A persistent health concern after COVID could be a bacterial infection lurking.
COVID, like other viral infections, can open the door to bacterial sinus infections.
A 49-year-old woman's story: She battled COVID, losing her senses of taste and smell. Despite recovering from COVID, these symptoms persisted. Then, a sudden, foul odor hit, followed by nasty drainage. A trip to the doctor confirmed a sinus infection, treated with antibiotics. But relief was short-lived; the horrible smell returned, accompanied by more drainage.
Here's where it gets controversial: Is this a long-term COVID side effect, or something else?
Dr. Roach's take: It's likely a bacterial sinus infection, given the improvement with antibiotics. Incomplete treatment could be the issue; sinus infections can be tricky, often requiring longer antibiotic courses. Some cases even need specialized testing.
The odour and discharge are tell-tale signs of a bacterial sinus infection.
A diabetes dilemma: Insulin vs. new GLP meds.
A type 2 diabetes patient's dilemma: Insulin or new GLP meds?
Tirzepatide (Mounjaro) and semaglutide (Rybelsus/Ozempic) are GLP-1 agonists with advantages over insulin for many. They aid weight loss, a common goal for type 2 diabetics, and offer better heart protection.
But here's the catch: The price. While most patients get coverage, side effects exist, and they're not for everyone.
And this is the part most people miss: Doctors prefer cheaper medications if they're as effective. By law, they can't profit from prescribing.
So, why the switch now? Likely, the heart or weight benefits convinced the doctors.
What's your take on these new GLP meds? Share your thoughts in the comments!
